Protagonist Therapeutics (PTGX) Long-Term Debt Issuances (2019 - 2023)

Protagonist Therapeutics has disclosed Long-Term Debt Issuances across 4 years of filings, most recently posting $24.3 million for Q1 2023.

• Long-Term Debt Issuances for Q1 2023 came in at $24.3 million, up 66.99% year-over-year; the trailing twelve-month figure through Dec 2023 was $24.3 million (up 66.99% YoY), and the FY2023 annual result was $24.3 million, up 66.99% from the prior year.
• Long-Term Debt Issuances came in at $24.3 million for Q1 2023 at Protagonist Therapeutics, up from $14.6 million in the prior quarter.
• In the past five years, Long-Term Debt Issuances ranged from a high of $34.0 million in Q3 2019 to a low of $6.4 million in Q3 2020.
• The 4-year median for Long-Term Debt Issuances is $18.8 million (2020), against an average of $19.6 million.
• Across the five-year window, Long-Term Debt Issuances slumped 81.23% in 2020 and surged 66.99% in 2023, its largest moves.
• Protagonist Therapeutics' Long-Term Debt Issuances stood at $34.0 million in 2019, then sank by 44.6% to $18.8 million in 2020, then fell by 22.77% to $14.6 million in 2022, then surged by 66.99% to $24.3 million in 2023.
• The last three Long-Term Debt Issuances figures came in at $24.3 million (Q1 2023), $14.6 million (Q1 2022), and $18.8 million (Q4 2020), per Business Quant data.